Preventing or attenuating amphotericin B nephrotoxicity with dopamine receptor agonists: a literature review

Preventing or attenuating amphotericin B nephrotoxicity with dopamine receptor agonists: a literature review

Show other versions (2)

Nephrotoxicity is generally considered as the most clinically significant and dose-limiting adverse reaction of amphotericin B. Currently, only the clinical effectiveness of salt loading and administering lipid formulations of amphotericin B have been clearly demonstrated to prevent its nephrotoxici...

Full description

Bibliographic Details
Main Authors:	Iman Karimzadeh, Hossein Khalili, Mohammad Mahdi Sagheb
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2015-07-01
Series:	Trends in Pharmaceutical Sciences
Online Access:	http://tips.sums.ac.ir/index.php/TiPS/article/view/37

Similar Items

Preventing or attenuating amphotericin B nephrotoxicity with dopamine receptor agonists: a literature review
by: Iman Karimzadeh, et al.
Published: (2015-09-01)

Preventing or attenuating amphotericin B nephrotoxicity with dopamine receptor agonists: a literature review
by: Iman Karimzadeh, et al.
Published: (2016-09-01)

Pentoxifylline in prevention of amphotericin B-induced nephrotoxicity and electrolyte abnormalities
by: Mahsa Panahi-Shokouh, et al.
Published: (2020-01-01)

Comparison of intravenous sodium bicarbonate and sodium chloride combination versus intravenous sodium chloride hydration alone in reducing amphotericin B nephrotoxicity: a randomized clinical trial
by: Iman Karimzadeh, et al.
Published: (2020-01-01)

Amphotericin B nephrotoxicity in patients with crytopococcal meningitis
by: Gerald, Maroka Kafofora
Published: (2018)

Amphotericin B-related nephrotoxicity in low-risk patients
by: Roberto Herz Berdichevski, et al.

Intralipid efficacy in decreasing Amphotericin B associated nephrotoxicity
by: Hasibi M, et al.
Published: (2013-03-01)

Reduction in the Nephrotoxicity of Amphotericin B when Administered in 20% Intralipid
by: Suzette Salama, et al.
Published: (1997-01-01)

Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity
by: Heather A. Personett, et al.
Published: (2019-01-01)

Vitamin D deficiency is a potential risk factor for lipid Amphotericin B nephrotoxicity.
by: Daniela Ferreira, et al.
Published: (2019-07-01)

Predictive Nephrotoxicity Profiling of a Novel Antifungal Small Molecule in Comparison to Amphotericin B and Voriconazole
by: Nadeeka S. Udawatte, et al.
Published: (2020-04-01)

Caffeic Acid Phenethyl Ester Protects against Amphotericin B Induced Nephrotoxicity in Rat Model
by: Atila Altuntaş, et al.
Published: (2014-01-01)

Arbutin attenuates nephrotoxicity induced by gentamicin
by: Elnaz Emadi, et al.
Published: (2021-05-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01)

Elucidating the mechanisms of agonist action at Dâ†2 dopamine receptors
by: Gardner, B.
Published: (1995)

Determination of agonist intrinsic efficacies at the dopamine D2 receptor
by: Stott, Lisa Alice
Published: (2017)

Dopamine D1 receptor agonist A68930 attenuates acute kidney injury by inhibiting NLRP3 inflammasome activation
by: Jing-Yuan Cao, et al.
Published: (2020-07-01)

Matricaria chamomilla attenuates cisplatin nephrotoxicity
by: Ragaa H.M. Salama
Published: (2012-01-01)

An investigation into the modulation of dopamine neurotransmission by typical antipsychotic agents and glycine_B receptor agonists
by: Bennett, Stephen Andrew
Published: (2005)

Potential Renoprotective Effects of Silymarin Against Nephrotoxic Drugs: A Review of Literature
by: Foroud Shahbazi, et al.
Published: (2012-01-01)

Response of Macroprolactinemia to Dopamine Agonists
by: Gonca Tamer, et al.
Published: (2008-01-01)

Dopamine Agonists for Pituitary Adenomas
by: Odelia Cooper, et al.
Published: (2018-08-01)

Dopamine Agonists and Pathologic Behaviors
by: Brendan J. Kelley, et al.
Published: (2012-01-01)

Studies in the synthesis of dopamine agonists
by: Cosford, Nicholas D. P.
Published: (1989)

Cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors
by: Prashant Donthamsetti, et al.
Published: (2021-08-01)

Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole
by: M. R. Nodel
Published: (2011-12-01)

Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
by: S N Illarioshkin
Published: (2012-06-01)

Interaction of permanently charged dopaminergic agonists and antagonists with D? dopamine receptors /
by: Farooqui, Tahira
Published: (1992)

Prevention of cisplatin nephrotoxicity
by: Hayati Fatemeh, et al.
Published: (2016-01-01)

Pramipexole, a dopamine D3/D2 receptor-preferring agonist, attenuates reserpine-induced fibromyalgia-like model in mice
by: Carlos Pereira Martins, et al.
Published: (2022-01-01)

An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety.
by: Armando Antillón, et al.
Published: (2016-01-01)

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
by: Maria Aigner, et al.
Published: (2020-05-01)

In vitro and in vivo investigations of the potential neuroprotective effects of propargylamines and dopamine receptor agonists
by: Wakselman, Shirley
Published: (2007)

The influence of G protein subtype on agonist action at the Dâ†2 dopamine receptors
by: Nickolls, Sarah Anne
Published: (2001)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
by: Line Aas Mortensen, et al.
Published: (2017-11-01)

Amphotericin B Revisited
by: Sahil Kumar, et al.
Published: (2021-01-01)

The biosynthesis of amphotericin B
by: McNamara, Carmel Marie
Published: (1996)

Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity.
by: Haruki Odaka, et al.
Published: (2014-01-01)

Dopamine Agonists Modify the Development of Brain D1 and D2 Receptor Responsiveness
by: Hamdi, Anwar A.
Published: (1990)

Dopamine Agonists Modify the Development of Brain D1 and D2 Receptor Responsiveness
by: Hamdi, Anwar A.
Published: (1990)

Cannot write session to /tmp/vufind_sessions/sess_dt2omi5lims47a0kejas6sjusu